NCT02844777View on ClinicalTrials.gov

Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

July 15, 2016

Primary Completion Date

May 26, 2017

Study Completion Date

May 26, 2017

Conditions
Actinic Keratosis
Interventions
DRUG

Placebo

200 mg applied once-daily for 28 days

DRUG

5% VDA-1102

200 mg applied once-daily for 28 days

DRUG

10% VDA-1102

200 mg applied once-daily for 28 days

Trial Locations (1)

92123

Therapeutics Clinical Research, San Diego

Sponsors

Lead Sponsor

Vidac Pharma
All Listed Sponsors
lead

Vidac Pharma

INDUSTRY

NCT02844777 - Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis | Biotech Hunter | Biotech Hunter